Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
Invivyd Inc. (IVVD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: IVVD (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $4.93
1 Year Target Price $4.93
| 1 | Strong Buy |
| 1 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 117.11% | Avg. Invested days 31 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 95.88M USD | Price to earnings Ratio - | 1Y Target Price 4.93 |
Price to earnings Ratio - | 1Y Target Price 4.93 | ||
Volume (30-day avg) 3 | Beta 0.52 | 52 Weeks Range 0.35 - 2.74 | Updated Date 08/15/2025 |
52 Weeks Range 0.35 - 2.74 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.19 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date 2025-08-19 | When - | Estimate -0.0233 | Actual -0.12 |
Profitability
Profit Margin - | Operating Margin (TTM) -149.7% |
Management Effectiveness
Return on Assets (TTM) -57.84% | Return on Equity (TTM) -122.69% |
Valuation
Trailing PE - | Forward PE 4.91 | Enterprise Value 48701182 | Price to Sales(TTM) 2.61 |
Enterprise Value 48701182 | Price to Sales(TTM) 2.61 | ||
Enterprise Value to Revenue 1.33 | Enterprise Value to EBITDA 0.78 | Shares Outstanding 119961000 | Shares Floating 49770804 |
Shares Outstanding 119961000 | Shares Floating 49770804 | ||
Percent Insiders 41.18 | Percent Institutions 60.76 |
Upturn AI SWOT
Invivyd Inc.
Company Overview
History and Background
Invivyd Inc. (IVVD), formerly Adagio Therapeutics, is a biotechnology company dedicated to developing and commercializing transformative antibody-based solutions for infectious diseases. The company was founded in 2020 and has focused on addressing viral threats, initially COVID-19.
Core Business Areas
- Antibody Therapeutics Development: Invivyd focuses on discovering, developing, and commercializing novel antibody therapies for infectious diseases. Their primary focus is on creating monoclonal antibodies that can neutralize viral threats.
Leadership and Structure
Invivyd's leadership team includes individuals with experience in biotechnology and drug development. The organizational structure is typical of a biotech company, with research, development, and commercialization divisions.
Top Products and Market Share
Key Offerings
- Vixivrev (formerly ADG20): Vixivrev is Invivyd's investigational monoclonal antibody designed to neutralize SARS-CoV-2 variants. Because the FDA revoked the Emergency Use Authorization for Vixivrev, there is no market share/revenue currently from this product.
Market Dynamics
Industry Overview
The biotechnology industry is highly competitive and characterized by rapid technological advancements and regulatory changes. Companies focus on developing innovative therapies to address unmet medical needs in areas like infectious diseases.
Positioning
Invivyd is positioned as a company focused on novel antibody therapeutics, particularly for emerging viral threats. Their competitive advantage lies in their ability to quickly develop and adapt antibody therapies to address new viral variants.
Total Addressable Market (TAM)
The TAM for infectious disease therapeutics is substantial, estimated to be in the billions of dollars. Invivyd's positioning allows it to capture a portion of this TAM by addressing specific viral threats and developing effective antibody solutions.
Upturn SWOT Analysis
Strengths
- Novel antibody platform
- Experienced leadership team
- Focus on unmet medical needs in infectious diseases
- Potential for rapid response to emerging viral threats
Weaknesses
- Reliance on single product candidate
- Dependence on regulatory approvals
- High cash burn rate
- Intense competition in the biotechnology sector
Opportunities
- Expansion of antibody platform to address other infectious diseases
- Partnerships and collaborations with other biotech and pharmaceutical companies
- Securing government funding and contracts
- Development of next-generation antibody therapies
Threats
- Clinical trial failures
- Regulatory delays or rejection of product candidates
- Competition from larger pharmaceutical companies
- Emergence of new viral variants that render existing therapies ineffective
Competitors and Market Share
Key Competitors
- LLY
- MRK
- AZN
Competitive Landscape
Invivyd faces competition from larger pharmaceutical companies with greater resources and established market presence. Its success depends on demonstrating the superior efficacy and safety of its antibody therapies.
Growth Trajectory and Initiatives
Historical Growth: The company has not yet generated significant revenue due to the developmental stage of its product candidates.
Future Projections: Future growth depends on successful clinical trials, regulatory approvals, and commercialization of its antibody therapies. Analyst projections vary and should be reviewed carefully.
Recent Initiatives: Recent initiatives include advancing Vixivrev through clinical development and exploring potential partnerships for expanding its product pipeline.
Summary
Invivyd is a development-stage biotechnology company focused on antibody therapeutics for infectious diseases. While its novel platform and experienced team are strengths, the company faces significant risks related to clinical trials, regulatory approvals, and competition. Its financial health relies heavily on future funding and successful commercialization. The revocation of the Emergency Use Authorization for Vixivrev is a significant setback. The company needs to diversify its pipeline to mitigate risk.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Invivyd Inc. SEC Filings (10-K, 10-Q)
- Company Website
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on your own due diligence and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Invivyd Inc.
Exchange NASDAQ | Headquaters Waltham, MA, United States | ||
IPO Launch date 2021-08-06 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 99 | Website https://invivyd.com |
Full time employees 99 | Website https://invivyd.com | ||
Invivyd, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's pipeline includes PEMGARDA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate, which is in preclinical studies for the prevention or treatment of COVID-19; and Adintrevimab that is in phase 2/3 clinical trials for the prevention and treatment of COVID-19. It also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. The company has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.